While this study has utilised PC3 cells, which model metastatic aggressive-variant, castrate-resistant PC with a defined set of genetic alterations including TP53 mutation and PTEN loss [51], extension to other stages of disease progression and mutational profiles is likely to yield further insights that can be exploited in the context of precision oncology. Here, TP53 is linked to pachyonychia congenita.